InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the full record of transactions filed by Protopapas Anna, Chairman & CEO. Officer active across 4 companies, notably Dicerna Pharmaceuticals Inc. In total, 15 filings have been logged. History available since 20 May 2022. The latest transaction was disclosed on 15 January 2025 (Levée d'options). Regulator: SEC (Form 4). All data is free.
Declarations15 total
21,250 shares0Common StockSEC:0001104659-25-004596:0
16,750 shares0Common StockSEC:0001104659-25-004187:0
31,250 shares0Common StockSEC:0001104659-25-003881:0
2,499 shares0Class A Common StockSEC:0000950170-24-073656:0
31,250 shares0Common StockSEC:0001104659-24-004551:0
5,000 shares@ US$9.36100.0% of flowClass A Common StockSEC:0001209191-23-059368:0
16,643 shares0Common StockSEC:0001104659-23-100443:0
240,244 shares0Common StockSEC:0001104659-23-004744:0
38,958 sharesCommon StockSEC:0001104659-22-005548
38,958 sharesCommon StockSEC:0001104659-22-005548:0
100,000 sharesCommon StockSEC:0001104659-21-093665
100,000 sharesCommon StockSEC:0001104659-21-093665:0
3,333 sharesCommon StockSEC:0001399529-21-000107
3,333 sharesCommon StockSEC:0001399529-21-000107:0
23,902 sharesCommon StockSEC:0001127602-16-039337:0
15 of 15 declarations
About Protopapas Anna
Anna Protopapas serves as President & CEO of Dicerna Pharmaceuticals Inc and Mersana Therapeutics, Inc. She leads the operations of both companies, ensuring that development strategies align with market needs. Her experience in the biopharmaceutical sector is an asset for the growth of these companies.
